At a glance
ClinicalIndex Comparison RecordN/ACompleted· 659 enrolled
Drug / intervention
Non-interventionbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post Marketing Surveillance To Observe Safety Of Prevenar 13 In Adults
In Brief
An observational study evaluating Non-intervention for Pneumococcal Disease. Completed, enrolled 659 participants across 27 sites.
Detailed Summary
The purpose of this study is to assess safety profile of Prevenar 13™ when used among Korean adults in the routine clinical setting, as required for any new drug approved by Korea Food and Drug Administration (KFDA).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Disease
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 2013
Enrollment StartDec 2013
Primary CompletionMar 2016
TodayJul 2026
First PostedApr 17, 2013
Enrollment StartDec 1, 2013
Primary CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 13.2 years ago
Interventions
Non-interventionbiological
Non-intervention